Tacrolimus (all routes)

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
All congenital malformations (majors, minors, majors and minors, or unspecified)1.77 [1.05, 2.98]0%4 studies58490not evaluable ROB
1 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Preterm (< 37 weeks)1.15 [0.51, 2.61]71%7 studies718577not evaluable ROB
Low birth weight (< 2500g)1.07 [0.68, 1.69]25%4 studies538503not evaluable ROB
Small for gestational age (weight)1.03 [0.29, 3.63]0%3 studies1929not evaluable ROB
1 non statistically significant endpoints reported in only one study

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Preeclampsia1.01 [0.81, 1.25]0%8 studies503767not evaluable ROB
Caesarean1.39 [1.00, 1.93]17%6 studies769572not evaluable ROB
Gestational diabete1.58 [1.07, 2.34]1%5 studies152755not evaluable ROB
Maternal death0.93 [0.15, 5.86]0%2 studies5117not evaluable ROB
3 non statistically significant endpoints reported in only one study

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Neonatal death (< 28 days of life)1.08 [0.43, 2.71]0%2 studies19442not evaluable ROB
2 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Early intrauterine death (< 22 weeks)1.48 [0.70, 3.16]37%3 studies324678not evaluable ROB
Late intrauterine deaths (> 22 weeks)0.65 [0.32, 1.33]0%4 studies36687not evaluable ROB
Therapeutic terminations of pregnancy0.28 [0.14, 0.56]-1 study68602not evaluable ROB
3 non statistically significant endpoints reported in only one study